In addition, although several therapies have been used as compensation for the cholinergic neuronal loss and reduction or prevention of amyloid/tau aggregation and toxicity, such as gene therapy, vaccines, anti-inflammatory agents [16], cholesterol-lowering agents, anti-oxidants [17], and hormone therapy [18] for AD, these single targeted therapies have often been unsuccessful [19,20]. The gene discussed is MAPT; the disease is Alzheimer disease.